iShares US Pharmaceuticals ETF
120 hedge funds and large institutions have $122M invested in iShares US Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 37 reducing their positions, and 15 closing their positions.
4% less capital invested
Capital invested by funds: $127M → $122M (-$4.55M)
5.08% less ownership
Funds ownership: 102.46% → 97.38% (-5.1%)
6% less funds holding
Funds holding: 127 → 120 (-7)
38% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 37
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$3.09M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.69M |
| 3 |
Jane Street
New York
|
-$2.35M |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$1.39M |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
-$1.36M |
IHE Hedge Fund Activity: Q2 2023 in Review
120 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2023, worth a combined $122M — down 3.6% from $127M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IHE and 9 opened new positions — a net loss of 6 holders — while 37 trimmed existing stakes and 23 added.
The largest buyer was Susquehanna International Group, adding an estimated $7.07M. The largest seller was Morgan Stanley, cutting an estimated $3.09M.
- 120 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2023, down from 127 in Q1 2023.
- Funds reported $122M of iShares US Pharmaceuticals ETF stock for Q2 2023, down 3.6% quarter-over-quarter.
- 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2023 and 15 closed out, a net change of -6 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2023 was Susquehanna International Group, an estimated $7.07M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2023 was Morgan Stanley, an estimated $3.09M sold.
Based on aggregated 13F filings for Q2 2023.